Mycobacterium tuberculosis is the leading global cause of death owing to an infectious agent, 24 accounting for approximately one in four antimicrobial resistance (AMR) fatalities annually. In 25 this study, we aimed to identify synergistic drug combinations with the capacity to restore 26 therapeutic efficacy against drug-resistant mutants of M. tuberculosis. To this end, we 27 investigated combinations containing the known translational inhibitors, spectinomycin (SPT) 28 and fusidic acid (FA), or the phenothiazine antibiotic, chlorpromazine (CPZ), which disrupts 29 mycobacterial energy metabolism. Potentiation was observed between SPT and CPZ. This effect 30 was lost against an M. tuberculosis mutant lacking the major facilitator superfamily (MFS) efflux 31 pump, Rv1258c. Notably, the SPT-CPZ combination restored SPT efficacy against an SPT-32 resistant mutant carrying a g1379t point mutation in rrs, encoding the mycobacterial 16S 33 ribosomal RNA. Combinations of SPT with FA, which targets the mycobacterial elongation 34 factor G (EF-G), exhibited potentiating activity against wild-type M. tuberculosis. Moreover, this 35 combination produced a small potentiating effect against defined FA-monoresistant and SPT-36 monoresistant mutants. Finally, combining SPT with the frontline anti-tuberculosis (TB) drugs, 37 rifampicin and isoniazid, resulted in enhanced activity in vitro and ex vivo against both drug-38 susceptible M. tuberculosis and a RIF-monoresistant rpoB S531L mutant.These results provide 39 evidence of the utility of novel potentiating drug combinations in restoring susceptibility against 40 M. tuberculosis strains carrying genetic resistance to any one of the partner drugs.
Introduction
times higher than the final concentration in the well as an overlay at sub-inhibitory 133 concentrations ranging from 1/32 to 1/2 of the single-drug MIC. Well A2 on all plates contained 134 the third drug only, providing the single-drug MIC for the third drug in each assay. After 135 inoculation with a log-phase culture of M. tuberculosis (50 µl) to each well, the plates were 136 placed in zip-lock bags and incubated for 7 days at 37°C before the results were read in the BMG 137 Labtech plate reader (excitation 544 nm; emission 590 nm). The mean fluorescence value for the 138 "maximum inhibition" wells (column 12) was subtracted from all other wells to control for 139 background fluorescence. Percent inhibition was defined as 1-(test well fluorescence units/mean 140 fluorescence units of maximum inhibition wells)  100 on day 8 after incubation. The lowest 141 drug concentration effecting inhibition of 90% was considered the MIC90. Alamar Blue dye was 142 used to visualize the 96-well microtitre plates.
143
Macrophage assays 144 Cell culture and maintenance 145 Human promonocytic THP-1 cells were maintained in RPMI-1640 medium (Sigma) 146 supplemented with 10% fetal bovine serum (FBS, Invitrogen) at an initial density of 8×10 5 147 cells/ml at 37 o C in a humidified, 5% CO2 atmosphere. Prior to plating of the cells, viability was 148 assessed by trypan blue exclusion method (30). Maturation of THP-1 cells into macrophages was 149 induced by adding 200 nM PMA (phorbol 12-myristate 13-acetate; Sigma) in cell culture 150 medium for 24 h. Differentiated macrophages were then washed with pre-warmed phosphate 151 buffer saline (PBS) three times to remove the PMA and replenished with cell culture medium. 152 Infection of macrophages and drug treatment 153 To check the efficacy of drugs in macrophages, 5×10 4 THP-1 cells/well/100µl in 96-well flat-154 bottomed tissue culture plates were differentiated into macrophages. To infect macrophages, an 155 exponentially growing M. tuberculosis H37Rv::(pSMYC::mCherry) culture was harvested by 156 centrifugation and washed twice with PBS. The pellet was resuspended in PBS and passed 157 through a 5 µm filter to generate a single bacterial suspension. The bacterial density was 158 quantified by measuring OD of bacterial suspension at 600 nm, correlating an OD600 ~0.5 to 159 1×10 8 CFU/ml. To make infection medium, the number of bacteria required to achieve a 160 multiplicity of infection (MOI) of 5:1 (5 bacilli to one macrophage cell) was added to the cell 161 culture medium (31). The cells were overlaid with infection medium and incubated at 37 o C in 162 5% CO2 for the phagocytic period of 3 h. Thereafter, cells were washed gently and thoroughly 163 with prewarmed PBS to remove extracellular bacteria. The cells from three wells were lysed in 164 triton X-100 (0.05% in PBS) and plated onto 7H10 to score colony forming units (CFUs) for day 165 zero. The cells used as un-treated control were refreshed with cell culture medium. The cells in 166 remaining wells were treated with the indicated antibiotic either alone or in combination at 1 167 MIC90 or 5 MIC90, as determined in liquid culture. Hygromycin was added into the cell culture 168 medium used for both untreated or treated cells to maintain the plasmid expressing mCherry.
169

Fluorescence measurement 170
The fluorescence of the mCherry reporter was measured at different time points on a BMG 171 Labtech plate reader (excitation 544 nm; emission 590 nm).
172
CFU enumeration 173
To count live bacteria after drug treatment, untreated and drug-treated M. tuberculosis-infected 174 cells were lysed in triton X-100 (0.05% in PBS) on days 2, 4 and 6, and serial dilutions of the 175 cell lysate were plated onto 7H10 agar. Colonies were counted after 3-4 weeks of incubation.
176
RESULTS
178
CPZ potentiates SPT activity by inhibiting Rv1258c-mediated efflux. The combination of 179 SPT and CPZ was previously reported as synergistic against M. smegmatis (32). When tested 180 against wild-type M. tuberculosis H37Rv (Fig. 1a) , the same combination yielded a sum 181 fractional inhibitory concentration (FIC) value of 0.09 (Table 1 ), suggesting strong synergy (33).
182
We next investigated whether this effect resulted from CPZ-mediated disruption of the activity 183 of the Major Facilitator Superfamily (MFS) efflux pump, Rv1258c, which has been implicated in 184 innate resistance to SPT (17). To investigate this possibility, we performed checkerboard assays 185 using the efflux-defective ΔRv1258c knockout mutant which was exploited in the development 186 of the spectinamides (SPD), (17) as well as its complemented derivative, ΔRv1258c pCRS4.
187
Both mutants exhibited the same MIC90 for CPZ (22 mg/L ; Fig. 1 & Table 1 ), whereas the 188 ΔRv1258c knockout mutant was hypersusceptible to SPT, returning an MIC90 of 3.9 mg/L ( Fig.   189 1b & Table 1) , as observed previously (34). Importantly, the synergy detected on exposing wild-190 type M. tuberculosis to a combination of CPZ and SPT ( Fig. 1a) was eliminated in the ΔRv1258c 191 mutant ( Fig. 1b) yielding an FIC value of 0.75 (Table 1) ,but restored in the 192 complemented ΔRv1258c pCRS4 strain ( Fig. 1c) SPT synergy is likely to derive from disrupted Rv1258c function in cells exposed to the 198 phenothiazine.
199
A spontaneous SPT-resistant mutant, SPT R , carrying a g1379t point mutation in the 200 mycobacterial 16S ribosomal RNA, rrs, was associated with >64-fold increase in the SPT MIC90.
201
In contrast, CPZ retained activity against this strainconfirming a mechanism of action 202 independent of rrs inhibition (36). Moreover, while SPT R was resistant to SPT at concentrations 203 > 248 mg/L in the absence of CPZ, combinations utilizing CPZ at sub-MIC concentrations 204 ([CPZ]  11.1 mg/L) restored SPT sensitivity, at least partially (Fig. 1d) . These results suggested 205 the capacity for synergistic combinations to restore drug activity against mutant strains 206 genetically resistant to either of the partner compounds. inhibitors which act at discrete steps of the elongation processwas tested against wild-type M. 215 tuberculosis and two resistant strains, FA R and SPT R . As noted above, the SPT R mutant carries a 216 g1379t mutation in rrs (32). Isolation of spontaneous FA R mutants yielded a strain carrying a 217 c1384t (H462Y) substitution in fusA1 (Rv0684), encoding the essential mycobacterial elongation 218 factor G (EF-G) (39). The histidine residue is highly conserved across multiple bacterial species 219 and, using the T. thermophilus structure as template (40), it has been inferred that M. 220 tuberculosis H462 corresponds to T. thermophilus H458 (41), mutations of which are likely to 221 alter the FA-binding pocket (42). In MIC assays, the H462Y mutant consistently yielded an 222 MIC90 ≥ 25 mg/L, confirming heritable FA R .
223
With these strains in hand, we evaluated the interaction between SPT and FA and, 224 furthermore, examined the potential to use potent combinations to counter pre-existing drug 225 resistance. The combination of SPT and FA returned a sum FIC value = 0.49 (Table 2) the MIC90 of SPT exhibited a 4-fold decrease from 248 mg/L to 62 mg/L ( Fig. 2a) . Notably, FA 228 restored the activity of SPT against a SPT R mutant (Fig. 2b) . Although not manifest as a 229 "synergistic" sum FIC (Table 2) , the effect was marked and reproducible, with sub-MIC 230 concentrations of FA (1.6 mg/L and 3.3 mg/L) achieving more than 90 % inhibition in 231 combination with SPT. The same combination did not return any synergy against the FA R mutant 232 (Fig 2c) , identifying FA as the major contributor to the SPT-FA combination. Table 3 233 summarizes the inhibitory effects demonstrated by the CPZ-SPT and FA-SPT combinations, S3a). A kill kinetics assay showed that the addition of SPT to the RIF-INH combination elicited 248 a 1 log10 unit reduction in the viable bacillary population following 8-day exposure to the drugs 249 ( Fig. S3b) . 250 Since M. tuberculosis survives and replicates in macrophages (43), the synergy of the 251 RIF-INH plus SPT combination was evaluated against intracellular bacilli in M. tuberculosis-252 infected THP-1 cells. The three-drug combination showed inhibitory activity at 1 MIC90 of the 253 combined drugs. (Fig. S4) . In contrast, the inhibitory effect was reduced when similar 254 concentrations of each drug were applied individually, or when the standard RIF-INH 255 combination was used. The intracellular activity of this triple combination was further confirmed 256 by CFU enumeration (Fig. S5) The capacity for evolution through mutagenesis means that it is difficult, even conceivably 268 impossible, to overcome antibiotic resistance sustainably (44). However, different approaches 269 can be used to circumvent resistance transiently, ensuring efficacy despite the pre-existence of 
284
This study reveals interaction between FA and SPT against drug-susceptible bacteria via 285 a mechanism independent of the efflux inhibition seen with SPT-CPZ. Notably, the same FA-286 SPT combination exerted a greater inhibitory effect against a genotypically confirmed SPT R 287 mutant compared to a FA R mutant. Although there is no definitive explanation for this finding, that the synergistic activity of the triplet combination might have multiplicative effects (10).
307
Here, SPT was deployed as part of a three-drug regimen which also included RIF and INH, the 308 two drugs that form the cornerstone of TB treatment. Previous studies have shown the interaction 309 between RIF and INH against M. tuberculosis to have no interaction or to be mildly antagonistic 310 (8, 53) . The inclusion of SPT in this drug regimen was underpinned by studies elsewhere, which 311 reported that 24 out of 70 random combinations tested were synergistically active in M. 312 smegmatis (10). This suggests a large unexplored pool of synergistic combinations. Notably,
313
SPT exhibited synergy with several compounds both in vitro and ex vivo (10), even though the 314 compound has high MIC90 against M. tuberculosis when administered on its own (17).
315
In the three-drug combination assay, synergy resulted when sub-inhibitory concentrations 316 (1/2x and 1/4x MICs) of SPT were titrated into media containing RIF and INH (Fig. S3a) . This 317 finding correlated well with the results of time-kill kinetics (Fig. S3b) . The time-kill assay 318 suggested, however, that the inhibitory effect of this three-drug interaction was bacteriostatic (0≥ 319 log10 CFU <3 reduction) and not bactericidal. This observation reveals that the combination of 320 RIF and INHtwo bactericidal drugs that are most potent with actively dividing cellsshows 321 bacteriostatic effects. Furthermore, the inhibition of growth induced by a bacteriostatic drug,
322
SPT, results in an overall static effect.when the drug is used in combination with a bactericidal 323 drug. Other studies have shown that in similar interactions, the resulting effect achieves a more 324 efficient clearance at lower concentrations (34).
325
In attempting to exploit synergy for potential optimal treatment outcomes, an 326 investigation of the RIF-INH plus SPT interaction was performed in rpoB and inhA mutants. The 327 RIF rpoB resistant strain had an MIC value >50 times the MIC90 for drug susceptible M. 328 tuberculosis (Table S1 ). Fig. 3a shows that the addition of 1/2 and 1/4 MICs of SPT also 
